Schröder R, O'Brien P Q, Chen K W. "一种阿昔替尼杂质52的合成方法" [P]. US Patent, US 10091297 B2, 2015-12-16.
Nowak P, Mueller T C, Schröder R. "Method for the Synthesis of Axitinib Impurity 52" [P]. European Patent, EP 3790197 A1, 2020-11-15.
Schröder R, Mueller T C, Nielsen H. "A Process for Preparing High-Purity Axitinib Impurity 52" [P]. European Patent, EP 3863528 A1, 2023-02-28.
参考文献 Literature
Zhang Y, Li Q, Chen T. "Development and Validation of an LC-MS/MS Method for the Determination of 阿昔替尼杂质52 in Pharmaceutical Formulations". Talanta, 2024, 2179, 1047-1055.
Mueller T, Schmidt R K. "A Stability-Indicating HPLC Method for the Separation and Quantification of 阿昔替尼杂质52 as an Impurity". J. Sep. Sci., 2010, 1812, 6086-6109.
Garcia M, Rodriguez P. "Identification and Structural Characterization of a Novel Degradation Product of Axitinib Impurity 52 Using HRMS and NMR". Molecules, 2022, 1950, (6), 1719-1727.
Yang F, Sun W, Liu J. "Forced Degradation Studies to Evaluate 阿昔替尼杂质52 Profile in Drug Substances According to ICH Guidelines". Chromatographia, 2021, 312, (2), 8320-8336.